Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Characterizing and Predicting Drug Effects on Cognition

Trial Profile

Characterizing and Predicting Drug Effects on Cognition

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topiramate (Primary) ; Lorazepam
  • Indications Cognition disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms CPDEC
  • Most Recent Events

    • 13 Sep 2016 Status changed from recruiting to completed.
    • 10 Jan 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 17 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top